Date: 2015-09-20
Type of information: Production agreement
Compound: OS2966
Company: CMC Biologics (Denmark - USA) Oncosynergy (USA-France)
Therapeutic area: Infectious diseases
Type agreement: production manufacturing
Action mechanism: monoclonal antibody. OS2966 is an anti-CD29 monoclonal antibody. OS2966 is a first in class therapeutic being investigated in multiple models of highly aggressive and resistant solid cancers. OS2966 selectively modulates CD29 (integrin b1 subunit), a critical path driver of multiple mechanisms of tumor growth and progression including proliferation, invasion, angiogenesis, and therapy resistance. Pre-clinical data suggest OS2966 may be active against numerous solid cancers including recurrent and therapy resistant glioblastoma.
Disease: Ebola fever
Details: * On December 16, 2014, CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the FDA earlier this year in the treatment of glioblastoma. Previous studies have suggested CD29 is required for Ebola virus infection; blocking CD29 could halt Ebola’s spread in the body. OS2966, a monoclonal antibody, is being investigated in multiple models of highly aggressive cancers and other diseases of high unmet need. Recently, in collaboration with multiple eminent Ebola scientists internationally, OncoSynergy has demonstrated OS2966 blocks the ability of Ebola virus to enter cells in laboratory models. Further studies, including primate models, are ongoing or in development. Proposed West Africa trials will examine safety and dosing and test the effectiveness of OS2966 against Ebola virus disease in humans.
Financial terms:
Latest news:
